Announcements Trials
Browse Landscape

Phase

Phase 2 221Phase 1 123Phase 3 50Phase 1/2 48Phase NA 6Phase 4 4Phase EARLY_PHASE1 3Phase 2/3 2

Status

Completed 3Terminated 2Recruiting 2Unknown 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Primary Myelofibrosis 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Multiple Myeloma 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1

Interventions

Magnetic Resonance Spectroscopy 23Metformin 14pembrolizumab 12Radiotherapy 12Biopsy 11Nivolumab 9Fluorouracil 9Cyclophosphamide 9Temozolomide 7Radiation 7Bevacizumab 7gallium 68 PSMA-11 6Sirolimus 6Rituximab 6Letrozole 6Etoposide 6Cisplatin 6Aspirin 6olaparib 5Surveys and Questionnaires 5Radiosurgery 5Oxaliplatin 5Irinotecan 5Indocyanine Green 5Granulocyte Colony-Stimulating Factor 5Fluorodeoxyglucose F18 5Dexamethasone 5aldesleukin 4Surgical Procedures, Operative 4Proflavine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Completed × Bortezomib × Clear all
NCT01594242 2019-04-16

Autophagy Induction After Bortezomib for Myeloma

Abramson Cancer Center at Penn Medicine

Phase EARLY_PHASE1 Completed
11 enrolled
Plasma cell

Multiple Myeloma

NCT01171092 2017-01-11

A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma

University of Kansas Medical Center

Phase EARLY_PHASE1 Completed
21 enrolled
LymphoidPlasma cell

Lymphoma, Neoplasms, Plasma Cell

NCT00437086 2014-10-17

Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders

Mayo Clinic

Phase EARLY_PHASE1 Completed
30 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡